Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions

Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis

(2016) Esther Korpershoek et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Adenoma hipofisario asociado a feocromocitoma/paraganglioma: una nueva forma de neoplasia endocrina múltiple

(2016) Fernando Guerrero Pérez et al.   Endocrinologia y Nutricion

15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas

(2015) Samuel M O'Toole et al.   ENDOCRINE-RELATED CANCER

Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort

(2015) Judit Dénes et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pituitary Adenoma With Paraganglioma/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice

(2015) Paraskevi Xekouki et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

(2012) N. Burnichon et al.   CLINICAL CANCER RESEARCH

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

(2011) Iñaki Comino-Méndez et al.   NATURE GENETICS

Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients

(2009) Jean-Pierre Bayley et al.   ENDOCRINE-RELATED CANCER

Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations inSDHBandSDHD

(2009) Christopher J. Ricketts et al.   HUMAN MUTATION